Susceptibility of HPV-18 Cancer Cells to HIV Protease Inhibitors [PDF]
VirusesCervical cancer cases continue to rise despite all the advanced screening and preventative measures put in place, which include human papillomavirus (HPV) vaccination.
Lilian Makgoo +2 more
doaj +2 more sources
Molecular Mechanisms of HIV Protease Inhibitors Against HPV-Associated Cervical Cancer: Restoration of TP53 Tumour Suppressor Activities [PDF]
Frontiers in Molecular Biosciences, 2022 Cervical cancer is a Human Papilloma virus-related disease, which is on the rise in a number of countries, globally. Two essential oncogenes, E6 and E7, drive cell transformation and cancer development.
Lilian Makgoo +2 more
doaj +2 more sources
HIV protease inhibitors restore amphotericin B activity against Candida. [PDF]
PLoS ONECandida auris is an invasive fungal pathogen, representing a global public health threat. It is characterized by high mortality rates among infected individuals, significant antifungal resistance, and a remarkable ability to persist in healthcare ...
Yehia Elgammal +2 more
doaj +2 more sources
HIV protease cleaves the antiviral m6A reader protein YTHDF3 in the viral particle. [PDF]
PLoS Pathogens, 2020 N6-methyladenosine (m6A) is the most abundant HIV RNA modification but the interplay between the m6A reader protein YTHDF3 and HIV replication is not well understood.
Denise Jurczyszak +9 more
doaj +2 more sources
Higher Desolvation Energy Reduces Molecular Recognition in Multi-Drug Resistant HIV-1 Protease
Biology, 2012 Designing HIV-1 protease inhibitors that overcome drug-resistance is still a challenging task. In this study, four clinical isolates of multi-drug resistant HIV-1 proteases that exhibit resistance to all the US FDA-approved HIV-1 protease inhibitors and ...
Ladislau C. Kovari +6 more
doaj +1 more source
Naturally Occurring Mutations in HIV-1 Protease Gene Among People Living With HIV
Acta Medica Iranica, 2023 The emergence of resistance to antiretroviral drugs is the main problem in their long-term efficacy and by considering the wide use of protease inhibitors (PIs), monitoring drug resistance mutations is necessary.
Zahra Hasanshahi +6 more
doaj +1 more source
Sensors, 2013 To effectively fight against the human immunodeficiency virus infection/ acquired immunodeficiency syndrome (HIV/AIDS) epidemic, ongoing development of novel HIV protease inhibitors is required.
Rok Gaber +3 more
doaj +1 more source
Drug Reprofiling to Identify Potential HIV-1 Protease Inhibitors
Molecules, 2023 The use of protease inhibitors in human immunodeficiency virus type 1 (HIV-1) treatment is limited by adverse effects, including metabolic complications. To address these challenges, efforts are underway in the pursuit of more potent and less toxic HIV-1
Sunday N. Okafor +7 more
doaj +1 more source
Inhibition Profiling of Retroviral Protease Inhibitors Using an HIV-2 Modular System
Viruses, 2015 Retroviral protease inhibitors (PIs) are fundamental pillars in the treatment of HIV infection and acquired immunodeficiency syndrome (AIDS). Currently used PIs are designed against HIV-1, and their effect on HIV-2 is understudied.
Mohamed Mahdi +3 more
doaj +1 more source
Low prevalence of hepatitis C co-infection in recently HIV-infected minority men who have sex with men in Los Angeles: a cross-sectional study. [PDF]
, 2015 BackgroundGeographic and sociodemographic characterization of hepatitis C virus (HCV) transmission amongst men who have sex with men (MSM) has been limited.
Bhattacharya, Debika +7 more
core +2 more sources